What is the appropriate unfractionated heparin dosing regimen for a patient who received therapeutic low‑molecular‑weight heparin (LMWH, e.g., enoxaparin) within the prior 24 hours before coronary angiography?

Heparin Dosing After Recent LMWH for Coronary Angiography

For patients who received therapeutic LMWH (enoxaparin) prior to coronary angiography, give additional unfractionated heparin (UFH) as needed to achieve an activated clotting time (ACT) of 250-300 seconds, rather than a fixed weight-based bolus dose.

Timing-Based Dosing Strategy

The critical factor is when the last LMWH dose was administered relative to the procedure:

If Last Enoxaparin Dose Was <8 Hours Before PCI

• No additional enoxaparin should be given 1, 2
• Give supplemental UFH as needed to achieve target ACT 250-300 seconds 1
• Typical supplemental doses range from 2,000-5,000 units IV 2

If Last Enoxaparin Dose Was 8-12 Hours Before PCI

• Give 0.3 mg/kg IV enoxaparin 1, 2
• Alternatively, give supplemental UFH to achieve target ACT 250-300 seconds 1

If Last Enoxaparin Dose Was >12 Hours Before PCI

• Treat as if no prior anticoagulation received
• Give 70-100 U/kg UFH bolus to achieve target ACT 250-300 seconds 1

Critical Safety Warning

Do NOT give UFH to patients already receiving therapeutic subcutaneous enoxaparin 2. This "stacking" of anticoagulants causes excessive anticoagulation that is not detected by ACT monitoring 3. The STACKENOX study demonstrated that adding UFH to patients on enoxaparin resulted in total inhibition of thrombin generation for ≥2 hours, yet ACT levels remained falsely reassuring 3.

Rationale for This Approach

The 2025 ACC/AHA/SCAI guidelines 1 provide the most current and authoritative recommendations, explicitly stating that patients who have received prior anticoagulant therapy should receive "additional UFH as needed to achieve an ACT 250-300 s" rather than full weight-based dosing. This approach:

• Prevents over-anticoagulation from stacking two anticoagulants
• Reduces bleeding risk while maintaining adequate procedural anticoagulation
• Accounts for residual enoxaparin effect, which has a longer half-life than UFH and delayed clearance in renal dysfunction 4

The 2011 ACCF/AHA/SCAI PCI guidelines 2 reinforce this with Class I evidence that an additional 0.3 mg/kg IV enoxaparin should be given if the last dose was 8-12 hours prior, and Class III (Harm) evidence that UFH should not be given to patients already receiving therapeutic enoxaparin.

Practical Implementation

1. Determine timing of last enoxaparin dose
2. Check baseline ACT before giving additional anticoagulation
3. Give targeted supplementation based on timing algorithm above
4. Recheck ACT 5-10 minutes after any heparin bolus
5. Avoid fixed-dose protocols that don't account for prior LMWH

Common Pitfalls to Avoid

• Do not use standard 70-100 U/kg UFH bolus in patients who received LMWH within 12 hours—this causes excessive anticoagulation 3
• Do not rely solely on ACT to guide dosing when enoxaparin and UFH are combined, as ACT underestimates the true anticoagulation effect 3
• Do not switch between enoxaparin and UFH back and forth, as this increases bleeding risk 5